Should I buy or sell RayzeBio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RayzeBio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYZB shares. View RYZB analyst ratings or view top-rated stocks .

What is RayzeBio's stock price target for 2024?

5 Wall Street analysts have issued 1 year price targets for RayzeBio's shares. Their RYZB share price targets range from $29.00 to $35.00. On average, they anticipate the company's share price to reach $31.33 in the next twelve months. This suggests that the stock has a possible downside of 49.7%. View analysts price targets for RYZB or view top-rated stocks among Wall Street analysts .

How have RYZB shares performed in 2024?

RayzeBio's stock was trading at $62.17 at the beginning of the year. Since then, RYZB shares have increased by 0.2% and is now trading at $62.32. View the best growth stocks for 2024 here .

When is RayzeBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024. View our RYZB earnings forecast .

When did RayzeBio IPO?

(RYZB) raised $311 million in an IPO on Friday, September 15th 2023. The company issued 17,277,600 shares at a price of $18.00 per share.

When does RayzeBio's lock-up period expire?

RayzeBio's lock-up period expires on Wednesday, March 13th. RayzeBio had issued 17,277,600 shares in its IPO on September 15th. The total size of the offering was $310,996,800 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.

Who are RayzeBio's major shareholders?

RayzeBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alpine Associates Management Inc. (1.27%), Franklin Resources Inc. (0.85%), Charles Schwab Investment Management Inc. (0.25%), Vivo Capital LLC (0.18%), UBS Group AG (0.16%) and Versor Investments LP (0.13%). Insiders that own company stock include Global Investors Lp Viking and Maha Katabi . View institutional ownership trends .

How do I buy shares of RayzeBio?

Shares of RYZB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:RYZB

RayzeBio (RYZB) Stock Price, News & Analysis

$62.32

+0.05 (+0.08%)

(As of 02/9/2024 08:56 PM ET)

Compare

Today's Range: $62.22
▼
$62.36
50-Day Range: $23.63
▼
$62.32
52-Week Range: $17.95
▼
$62.36

Volume: 315,300 shs
Average Volume: 634,211 shs
Market Capitalization: $3.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $31.33

Get RayzeBio alerts:

About RayzeBio Stock (NASDAQ:RYZB)

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California.

RYZB Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RYZB Stock News Headlines

December 31, 2023 | businesswire.com

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

December 31, 2023 | businesswire.com

RAYZEBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of RayzeBio, Inc. - RYZB

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

December 28, 2023 | realmoney.thestreet.com

RayzeBio just downgraded at JPMorgan, here's why

December 28, 2023 | msn.com

RBC says Bristol Myers/RayzeBio deal validates Fusion 's approach

December 28, 2023 | realmoney.thestreet.com

RayzeBio downgraded to Hold from Buy at Truist

December 26, 2023 | finance.yahoo.com

Bristol Myers' $4.1 Billion Deal For RayzeBio Sends RYZB Stock Soaring 100%

December 26, 2023 | msn.com

Why RayzeBio Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

February 12, 2024 | The Freeport Society (Ad)

New Trump Bombshell

I believe Donald J. Trump will go down as America’s last Republican president. But NOT for the reasons you may think… If I’m right, the soul of this country will change forever…

December 26, 2023 | finance.yahoo.com

Bristol Myers buying RayzeBio, FedEx buyback: Trending tickers

December 26, 2023 | za.investing.com

Midday movers: Intel, RayzeBio, and more

December 26, 2023 | benzinga.com

Health Care Company Bristol-Myers Squibb Announces Merger With RayzeBio

December 26, 2023 | tmcnet.com

RYZB Stock Alert: Halper Sadeh LLC Is Investigating RayzeBio, Inc.

December 26, 2023 | seekingalpha.com

RayzeBio: New IPO With Good Data And Solid Premise

December 26, 2023 | msn.com

Bristol-Myers Agrees Deal to Buy RayzeBio for About $4.1 Billion

December 26, 2023 | finance.yahoo.com

Bristol Myers,RayzeBio deal, AstraZeneca buying Gracell

December 26, 2023 | investorplace.com

Why Is RayzeBio (RYZB) Stock Up 100% Today?

December 26, 2023 | finance.yahoo.com

Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio

December 12, 2023 | seekingalpha.com

Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q3 2023 Update

December 3, 2023 | benzinga.com

RayzeBio Stock (NASDAQ:RYZB) Dividends: History, Yield and Dates

November 30, 2023 | markets.businessinsider.com

Truist Financial Keeps Their Buy Rating on RayzeBio, Inc. (RYZB)

November 30, 2023 | morningstar.com

RayzeBio inc RYZB

November 13, 2023 | finance.yahoo.com

RayzeBio Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 6, 2023 | finance.yahoo.com

RayzeBio to Participate in Upcoming Investor Conferences in November 2023

November 1, 2023 | finance.yahoo.com

RayzeBio Appoints Industry Leader Tim Van Hauwermeiren to Its Board of Directors

October 24, 2023 | finance.yahoo.com

FDA selects RayzeBio to Participate in the Inaugural CDRP Program to Expedite Commercial Manufacturing Readiness for RYZ101 in GEP-NETs

October 18, 2023 | finance.yahoo.com

RayzeBio to Present at European Society for Medical Oncology (ESMO) Congress

See More Headlines

Receive RYZB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RayzeBio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/13/2023
Today: 2/11/2024
Next Earnings (Estimated): 2/12/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:RYZB
CUSIP: N/A
CIK: 1825367
Web: rayzebio.com
Phone: 619-937-2754
Fax: N/A
Employees: 88
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $31.33
High Stock Price Target: $35.00
Low Stock Price Target: $29.00
Potential Upside/Downside: -49.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 31.85
Quick Ratio: 31.85

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: 59,920,000
Free Float: N/A
Market Cap: $3.73 billion
Optionable: Optionable
Beta: N/A

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Kenneth Song M.D. (Age 49)
President, CEO & Director
Comp: $646k
Mr. Arvind Kush (Age 41)
Chief Financial Officer
Comp: $714.76k
Dr. Susan Moran M.D. (Age 55)
Chief Medical Officer
Comp: $559.84k
Mr. Aron Marc Knickerbocker (Age 55)
Co-Founder
Mr. Jeff Woodley
General Counsel
Mr. Eric Bischoff
Senior Vice President of Development & Operations
Dr. Gary G. Li Ph.D.
Senior Vice President of Biology & Translational Medicine
Ms. Kimberly Ma M.S.
Senior Vice President of Clinical Operations
Dr. Nicholas D. Smith Ph.D.
Senior Vice President of Chemistry Innovation
Mr. Abhi Bhat Ph.D.
Senior VP of Chemistry & Head of Discovery

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RYZB Stock Analysis - Frequently Asked Questions

Should I buy or sell RayzeBio stock right now?: 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for RayzeBio in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" RYZB shares.
View RYZB analyst ratings or view top-rated stocks.
What is RayzeBio's stock price target for 2024?: 5 Wall Street analysts have issued 1 year price targets for RayzeBio's shares. Their RYZB share price targets range from $29.00 to $35.00. On average, they anticipate the company's share price to reach $31.33 in the next twelve months. This suggests that the stock has a possible downside of 49.7%.
View analysts price targets for RYZB or view top-rated stocks among Wall Street analysts.
How have RYZB shares performed in 2024?: RayzeBio's stock was trading at $62.17 at the beginning of the year. Since then, RYZB shares have increased by 0.2% and is now trading at $62.32.
View the best growth stocks for 2024 here.
When is RayzeBio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our RYZB earnings forecast.

When did RayzeBio IPO?: (RYZB) raised $311 million in an IPO on Friday, September 15th 2023. The company issued 17,277,600 shares at a price of $18.00 per share.
When does RayzeBio's lock-up period expire?: RayzeBio's lock-up period expires on Wednesday, March 13th. RayzeBio had issued 17,277,600 shares in its IPO on September 15th. The total size of the offering was $310,996,800 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the expiration of the lock-up period.
Who are RayzeBio's major shareholders?: RayzeBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alpine Associates Management Inc. (1.27%), Franklin Resources Inc. (0.85%), Charles Schwab Investment Management Inc. (0.25%), Vivo Capital LLC (0.18%), UBS Group AG (0.16%) and Versor Investments LP (0.13%). Insiders that own company stock include Global Investors Lp Viking and Maha Katabi.
View institutional ownership trends.
How do I buy shares of RayzeBio?: Shares of RYZB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RYZB) was last updated on 2/12/2024 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RayzeBio (RYZB) Stock Price, News & Analysis

About RayzeBio Stock (NASDAQ:RYZB)

RYZB Stock Price History

RYZB Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RYZB Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info